Teva Pharmaceutical Industries Ltd (NYSE:TEVA)‘s stock had its “underperform” rating reissued by equities researchers at Mizuho in a research report issued on Thursday. They currently have a $25.00 target price on the stock, down from their prior target price of $29.00. Mizuho’s price target indicates a potential downside of 12.92% from the stock’s current price.

Several other research analysts have also recently weighed in on TEVA. Royal Bank of Canada reissued an “outperform” rating and issued a $38.00 price target (down from $42.00) on shares of Teva Pharmaceutical Industries in a report on Monday, May 15th. Citigroup Inc reissued a “buy” rating and issued a $47.00 price target on shares of Teva Pharmaceutical Industries in a report on Tuesday, February 7th. Vetr cut shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $40.48 price target on the stock. in a report on Thursday, February 16th. Credit Suisse Group AG reaffirmed a “buy” rating and set a $39.00 target price on shares of Teva Pharmaceutical Industries in a report on Wednesday, May 17th. Finally, Maxim Group lowered their target price on shares of Teva Pharmaceutical Industries from $41.00 to $40.00 and set a “hold” rating on the stock in a report on Monday, February 13th. One equities research analyst has rated the stock with a sell rating, thirteen have issued a hold rating and fourteen have given a buy rating to the company’s stock. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and an average target price of $43.91.

Analyst Recommendations for Teva Pharmaceutical Industries (NYSE:TEVA)

Teva Pharmaceutical Industries (NYSE:TEVA) traded down 0.93% during trading on Thursday, hitting $28.71. The stock had a trading volume of 8,204,213 shares. Teva Pharmaceutical Industries has a 12-month low of $28.06 and a 12-month high of $56.44. The stock has a 50 day moving average price of $31.22 and a 200 day moving average price of $34.30. The company has a market capitalization of $29.17 billion, a price-to-earnings ratio of 368.08 and a beta of 0.58. Teva Pharmaceutical Industries also was the recipient of some unusual options trading activity on Wednesday. Stock traders acquired 963 put options on the stock. This is an increase of 113% compared to the average volume of 452 put options.

Teva Pharmaceutical Industries (NYSE:TEVA) last released its quarterly earnings results on Thursday, May 11th. The company reported $1.06 earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of $1.06. The firm had revenue of $5.63 billion for the quarter, compared to analysts’ expectations of $5.69 billion. Teva Pharmaceutical Industries had a net margin of 1.50% and a return on equity of 17.46%. The business’s revenue was up 17.0% on a year-over-year basis. During the same period in the prior year, the firm earned $1.20 EPS. Equities research analysts forecast that Teva Pharmaceutical Industries will post $4.81 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 22nd. Investors of record on Monday, June 5th will be paid a dividend of $0.34 per share. This represents a $1.36 dividend on an annualized basis and a yield of 4.74%. The ex-dividend date is Thursday, June 1st. Teva Pharmaceutical Industries’s dividend payout ratio is presently 1,657.38%.

WARNING: “Mizuho Reiterates “Underperform” Rating for Teva Pharmaceutical Industries Ltd (TEVA)” was first posted by American Banking News and is owned by of American Banking News. If you are reading this piece on another publication, it was copied illegally and reposted in violation of U.S. & international copyright & trademark law. The original version of this piece can be viewed at https://www.americanbankingnews.com/2017/05/25/mizuho-reiterates-underperform-rating-for-teva-pharmaceutical-industries-ltd-teva.html.

A number of institutional investors have recently made changes to their positions in TEVA. Cardinal Capital Management increased its position in shares of Teva Pharmaceutical Industries by 4.4% in the third quarter. Cardinal Capital Management now owns 57,624 shares of the company’s stock worth $2,651,000 after buying an additional 2,418 shares in the last quarter. SOL Capital Management CO increased its position in shares of Teva Pharmaceutical Industries by 5.8% in the third quarter. SOL Capital Management CO now owns 34,447 shares of the company’s stock worth $1,585,000 after buying an additional 1,900 shares in the last quarter. Heritage Investors Management Corp increased its position in shares of Teva Pharmaceutical Industries by 17.5% in the first quarter. Heritage Investors Management Corp now owns 188,990 shares of the company’s stock worth $6,065,000 after buying an additional 28,135 shares in the last quarter. Schulhoff & Co. Inc. increased its position in shares of Teva Pharmaceutical Industries by 9.5% in the first quarter. Schulhoff & Co. Inc. now owns 11,601 shares of the company’s stock worth $372,000 after buying an additional 1,004 shares in the last quarter. Finally, Diversified Trust Co increased its position in shares of Teva Pharmaceutical Industries by 1.9% in the third quarter. Diversified Trust Co now owns 58,707 shares of the company’s stock worth $2,701,000 after buying an additional 1,100 shares in the last quarter. 55.03% of the stock is owned by institutional investors and hedge funds.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.

12 Month Chart for NYSE:TEVA

Receive News & Ratings for Teva Pharmaceutical Industries Ltd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries Ltd and related companies with MarketBeat.com's FREE daily email newsletter.